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research over the last two decades has indicated that vita-
min D may also be a critical modulator of several non-
skeletal systems and related diseases. Vitamin D refers to 
two biological precursors – ergocalciferol (D 2 ) and chole-
calciferol (D 3 ). Vitamin D 3 constitutes around 80–90% of 
the circulating metabolites and is synthesized mainly in the 
skin by the action of ultraviolet (UV) light (280–315 nm). 
Vitamin D 3 can also be obtained exogenously from animal 
sources such as fish oils or fortified dairy products and vi-
tamin supplements. Sun-dried mushrooms, UV-B irradia-
tion of the yeast sterol ergosterol, as well as vitamin supple-
ments are considered as main sources of vitamin D 2  [2] . 
Vitamin D (D 2 , D 3 ) has no biological activity without a 
two-step hydroxylation process. The first step, in the liver, 
requires P450 enzymes such as CYP2R1 and CYP27A1 
(25-hydroxylases) to form the major circulating form 
25(OH)D. The second step, in the kidneys, requires the 
P450 enzyme, CYP27B1 (1α,25-hydroxylase) to form the 
main active metabolite – 1,25(OH)D or calcitriol. The sec-
ond hydroxylation reaction is stimulated mainly by para-
thyroid hormone (PTH), and inhibited by calcium, phos-
phate and fibroblast growth factor-23 (FGF-23)  [3] . The 
biological action of 1,25(OH) 2 D is mediated through the 
vitamin D receptors (VDRs) and this receptor as well as 
CYP27B1 are expressed widely in several tissues  [4] ( fig. 1 ).
 Vitamin D deficiency has been defined by the Institute 
of Medicine (IOM) as a measured serum 25(OH)D of <30 
nmol/l (12 ng/ml), vitamin D insufficiency when the se-
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 Abstract 
 In recent years there has been increasing interest in the non-
skeletal effects of vitamin D. It has been suggested that vita-
min D deficiency may influence the development of diabe-
tes, cardiovascular dysfunction and autoimmune diseases. 
This review focuses on the current knowledge of the effects 
of vitamin D and its deficiency on cardiovascular function, 
glucose homeostasis and immune function, with a particular 
focus on children. Although, there is good evidence to show 
that there is an association between vitamin D deficiency 
and an abnormality of the above systems, there is little evi-
dence to show that vitamin D supplementation leads to an 
improvement in function, especially in childhood. 
 © 2014 S. Karger AG, Basel 
 Vitamin D Overview 
 Most plants and animals that are exposed to sunlight 
have the ability to produce vitamin D. In humans, the ac-
tive vitamin D metabolite, 1,25-dihydroxyvitamin D 
(1,25(OH) 2 D), has been well recognized for its role in cal-
cium and phosphate homeostasis  [1] . However, intensive 
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rum 25(OH)D is 30 to <50 nmol/l (12 to <20 ng/ml) and 
vitamin D sufficiency is defined at 25(OH)D levels equal 
to 50 nmol/l (20 ng/ml)  [5] . There are a number of guide-
lines which have been published over the last decade to 
evaluate, manage and prevent vitamin D deficiency  [6–8] . 
However, there is little consensus on the threshold which 
reflects biological vitamin D sufficiency at the end-organ 
level. In addition, there is substantial uncertainty about 
the extraskeletal benefits of vitamin D supplementation, 
especially in those who have relatively mild vitamin D 
 Fig. 1. Photochemical synthesis of vitamin D and main target tis-
sues. Classical pathway of vitamin D and calcium homeostasis. A 
drop in the serum calcium stimulates an increase in the secretion 
of PTH and mobilizes further calcium from the bone. PTH in-
creases the synthesis of 1,25(OH) 2 D in the kidney, which, in turn, 
stimulates the mobilization of calcium from bone and intestine 
and regulates the synthesis of PTH by negative feedback. GH = 
Growth hormone; IGF-1 = insulin-like growth factor-1; GI = gas-
trointestinal. 
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deficiency  [6, 9] . In this review, PubMed and the Web of 
Knowledge were used to identify studies that explored a 
link between vitamin D, glucose homeostasis and cardio-
vascular and immune function in children. Studies con-
ducted within the last 7 years, which involved large pae-
diatric samples and those reported in English, were se-
lected and are summarized in  tables 1–3 as appropriate.
 Link between Vitamin D and Glucose Homeostasis – 
Putative Mechanisms 
 Evidence for an association between vitamin D and 
glucose homeostasis was first raised in reports of lower 
serum 1,25(OH)D level in diabetic rats compared to the 
control animals, and restoration of 1,25(OH)D to a nor-
mal level after insulin treatment  [10] . Coexisting hypovi-
taminosis D and abnormal glucose metabolism has also 
been reported in patients with type 2 diabetes mellitus 
(T2DM) compared to healthy controls  [11] and a possible 
link with vitamin D was also raised when a seasonal vari-
ation in plasma glucose and insulin was observed in nor-
mal individuals  [12] .
 There were several suggested biological mechanisms 
by which vitamin D may contribute to the development 
of T2DM. This evidence includes the presence of VDRs 
and the expression of 1α-hydroxylase enzymes in the 
pancreatic β cell along with the existence of a vitamin D 
response element in the human insulin gene promoter 
 [13–15] . In accordance with this finding, a significant 
 Table 1.  Summary of studies reporting association between 25(OH)D and glucose homeostasis in fasted state (boys and girls)
Reference Age,
years
BMI n Method 25(OH)D,
nmol/l
Association
with glucose
homeostasis
Adjusted
for variable
Comment
Reinehr
et al. [36]
12.1±2.4 27.7±3.8 133 glucose, insulin 50 no BMI longitudinal study 
(1 year)
Smotkin-Tan-
gorra
et al. [37]
12.9±5.5 32.3±6.4 217 glucose, insulin 55.2% <50,
44.8% ≥50
no no retrospective study
Delvin
et al. [155]
9, 13, 16 20.1±4.2 (boys),
20.4±4.5 (girls)
1,745 glucose, insulin 45.9±13 (boys),
45.9±12.2 (girls)
yes age, sex, BMI, smoking,
income, activity
–
Ford
et al. [156]
12–17
(range)
– 1,941 glucose, insulin, 
HbA1C
59 yes age, sex, BMI,
ethnicity, activity
vitamin intake, HDL
association with insulin 
resistance in selected 
subgroups
Kelly
et al. [157]
11±4 2.1(–1.2, 4.1)
(median
(min, max))
85 glucose, insulin,
HbA1C
59±32 yes age, sex, season, 
ethnicity, BMI,
puberty
correlation between 
HOMA and race, sex, 
season disappears after 
adjustment to puberty 
and BMI-Z
Olson
et al. [39]
6–16
(range)
99.2
(percentile
for age)
411 glucose, insulin, 
OGTT, HbA1C
49±17.8 yes age, BMI correlation exists only 
after adjustment; no 
correlation with HBa1C 
Roth
et al. [40]
11.9±2.7 SDS-BMI;
20% (non-
obese),
80% (obese)
156 glucose, insulin,
HbA1C
39.4±6.6 yes age, sex, BMI no impact of adiposity 
on study result
Poomthavorn
et al. [38]
11.2±2.6 28.6±4.8 150 OGTT (obese), 
glucose (non-
obese), insulin
70.4 no no subjected to selection 
bias as recruited from 
obesity clinic
Nsiah-Kumi
et al. [41]
10.8±0.3 77.0±1.7
(percentile for
age and sex)
198 glucose, insulin,
2 h blood
glucose
42.4 (16.9, 99.8)
(median
(min, max))
yes BMI –
 OGTT = Oral glucose tolerance test; HbA1C = glycosylated haemoglobin; BMI = body mass index; BMI-SDS = body mass index-standard deviation 
score. Data are shown as mean (SD), unless indicated otherwise.
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reduction in the insulin secretion in VDR mutant mice 
has been observed  [16] and the human insulin gene has 
been shown to be transcriptionally activated by 
1,25(OH) D 3  [17] . Vitamin D may influence insulin se-
cretion indirectly through its role in the regulation of 
calcium flux through the cell membrane combined with 
its role in the synthesis and regulation of calbindin, a vi-
tamin D-dependent Ca-binding protein in pancreatic β 
cells  [18] . Vitamin D may also protect β cells from fatal 
immune attacks, or programmed cell death either direct-
ly or through its effect on various components of innate 
and adaptive immune system at different levels (as dis-
cussed later). It has been reported that 1,25(OH)D 3 may 
counteract apoptotic pathways and the inflammatory ef-
fect induced by cytokines through inactivation of NF-κB 
antiapoptotic protein and suppression of Fas receptor 
expression  [19, 20] .
 Another possible mechanism explaining the involve-
ment of vitamin D in the pathogenesis of T2DM is the 
role of hypovitaminosis D in enhancing insulin resis-
tance at the target tissues  [21, 22] . The presence of the 
VDR in extraskeletal target sites, such as skeletal mus-
cle, together with the upregulation of insulin receptors 
(INS-R) after 1,25-hydroxyvitamin D 3 treatment ap-
pears to support this hypothesis  [23] . Elevated PTH has 
also been suggested as a modulator for both insulin sen-
sitivity and secretion status by affecting glucose uptake 
and inhibiting insulin transport signalling in the target 
tissues primarily by increasing intracellular calcium 
concentration  [24] . Chronic inflammation may worsen 
insulin resistance and vitamin D may influence the in-
flammatory reaction through several mechanisms in-
cluding modulation of the release of inflammatory cy-
tokines such as tumour necrosis factor-α (TNF-α), reg-
 Table 2.  Summary of studies reporting association between 25(OH)D and cardiovascular (CV) risk factors in children (boys and girls)
Reference Age, years BMI n Outcome 
assessed
25(OH)D,
nmol/l
Association
with CV
risk factors
Adjusted
for variable
Comment
Smotkin- 
Tangorra 
et al. [37]
12.9±5.5 32.3±6.4 217 BP, lipids 55.2% <50,
44.8% ≥50
yes no vitamin D insufficiency 
associated with ↑BMI, 
↑SBP, ↓HDL-C
Reis
et al. [82]
12–19 17.6 (≥95th 
percentile)
3,528 BP, lipids 61.9 yes age, gender, 
race, income,
activity, BMI
positive association 
with BP even after 
 adjustment 
Delvin
et al. [155]
9, 13, 16 20.1±4.2 (boys),
20.4±4.5 (girls)
1,745 lipids 45.9±12.2 (boys),
45.9±13 (girls)
yes age, sex, BMI,
smoking,
income, activity
positive association 
only present in girls
Dong
et al. [91]
16.3±1.4 61.6±33.4
(percentile)
23 (study)
21 (control)
BP, adiposity,
arterial
stiffness
33.4 yes age, sex 16-week randomized 
control trial of 2,000 IU 
daily 25(OH)D 
 supplementation
Pacifico
et al. [83]
11.5 (lowest),
11.2 (middle),
11 (highest)
24 (lowest),
22 (middle),
21 (highest)
452 BP, lipids,
endothelial
dysfunction
29.9 (lowest),
54.9 (middle),
89.8 (highest)
(median)
yes age, sex,
Tanner stage,
BMI
data divided according 
to serum 25(OH)D 
tertiles; an association 
with BP and lipids
Patange
et al. [158]
14.7±2.6 23.6±7.5 34 arterial 
compliance, left
ventricular mass,
diastolic function
38.21±23.41 yes – subjects had chronic 
renal disease; vitamin 
D deficiency associated 
with ↑ left ventricular 
mass and diastolic 
dysfunction
Nsiah-Kumi
et al. [41]
10.8±0.3 77.0±1.7 
(percentile for
age and sex)
198 BP, lipids, 
hsCRP
42.4 (16.9, 99.8)
(median
(min, max))
yes BMI –
 BMI  = Body mass index; BP  = blood pressure; hsCRP  = high-sensitivity C-reactive protein. Data are shown as mean (SD), unless indicated 
 otherwise.
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ulation of the activity of NF-κB, regulation of genes 
encoding pro-inflammatory cytokines and downregula-
tion of Toll-like receptor (TLR)2 and TLR4 expression 
 [25–27] .  Figure 2 illustrates the putative role of vitamin 
D on insulin synthesis, release and β-cell function.
 Link between Vitamin D and Glucose Homeostasis –
Evidence from Observational Studies 
 In a cross-sectional study, Orwoll et al.  [28] reported 
no relationship between serum 25(OH)D, fasting or 
post-challenge glucose and insulin secretion. However, 
the indirect method for measuring insulin level and un-
adjusted results for confounders may have had an impact 
on the study outcome. A positive association between 
25(OH)D and insulin secretion has been reported in 
both glucose-intolerant East London women of South 
Asian origin  [29] and healthy Caucasian elderly men 
 [30] . These studies were performed using an oral glucose 
tolerance test and have been further supported by other 
studies which used a hyperglycaemic clamp technique 
 [31, 32] .
 Indeed, most of the available cross-sectional studies, 
including a large data from the National Health and Nu-
trition Examination Survey (NHANES), support an in-
verse relationship between serum 25(OH)D and glycae-
mia and insulin resistance. However, the result from this 
survey was applied only to particular ethnic groups, non-
Hispanic White and Mexican-American but not non-
Hispanic Black  [33] . Prospective studies assessing the as-
sociation between 25(OH)D and diabetes risks are very 
limited. A negative association between basal serum con-
centration of 25(OH)D level and future hyperglycaemia 
and insulin resistance has been found in one prolonged 
study conducted over a 10-year period  [34] . A recent sys-
tematic review and meta-analysis showed that each 
10-nmol/l increase in 25(OH)D levels was associated 
with a 4% lower risk of T2DM. In addition, the relative 
risk of T2DM was 0.62 (95% CI 0.54–0.70) when com-
 Table 3.  Summary of studies reporting association between 25(OH)D and immunity in children (boys and girls)
Reference Age n 25(OH)D, nmol/l Outcome
assessed
Association
with outcome
Comment
Observational studies
Wright
et al. [159]
16 years
(median)
38 44.9 severity
of SLE
yes 25(OH)D lower in SLE patients (African origin & obese) 
compared with control (36.8 vs. 9.2%, p < 0.001)
Peroni
et al. [160]
5.6 years 37 92.1±39.1 (mild AD),
68.6±21.4 (moderate),
51.1±14.7 (sever AD)
severity
of AD
yes 25(OH)D higher in mild AD compared with moderate 
and severe AD (p < 0.05)
Greer
et al. [161]
10.1±0.9
years
56 81.4 (T1DM),
70.5 (newly diagnosis)
T1DM yes 25(OH)D lower in children with T1DM compared with 
controls [mean (95% CI) = 78.7 nmol/l (71.8–85.6) vs. 
91.4 nmol/l (83.5–98.7), p = 0.02]
Allen
et al. [162]
12.7±0.7
months
928 – infantile
food allergy
yes infants of Australian parents with 25(OH)D ≤50 nmol/l 
were more likely to be allergic to peanuts (aOR, 11.51; 
95% CI 2.01–65.79; p = 0.006) and/or EGG (aOR, 3.79; 
95% CI 1.19–12.08; p = 0.025)
Interventional studies
Manaseki-Holland
et al. [153]
13.18±9.1
years
224 – reduction of
pneumonia
attack 
yes children received 100,000 IU vitamin D3 along with AB; 
decreased risk of repeat episode in treatment group 
(92/204; 45%) compared with control (122/211; 58%)
Camargo
et al. [152]
10.1±0.9
years
143 17.47 ARIs attack
in winter 
yes children received milk fortified with 300 IU of vitamin 
D3; reduction in ARIs attack in treatment group com-
paring with control (aOR 0.52 (95% CI 0.31–0.89))
Manaseki-Holland
et al. [154]
1–11
months
(range)
1,487 – incidence of
pneumonia
no children received 100,000 IU vitamin D3 every 3 months 
for 18 months; no effect of vitamin D on the frequency 
of pneumonia episodes
 SLE = Systemic lupus erythematosus; AD = atopic dermatitis; AB = antibiotics; ARIs = respiratory infections; T1DM = type 1 diabetes mellitus; aOR = 
Adjusted odds ratio. Data are shown as mean (SD), unless indicated otherwise.
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paring the highest to the lowest category of 25(OH)D 
levels  [35] .
 Based on the available observational studies, little is 
known about the association between insulin sensitivity/
resistance, glucose intolerance and vitamin D deficiency 
in the paediatric population. Three studies have failed to 
find any association between vitamin D and insulin resis-
tance in obese children  [36–38] . Other studies report an 
inverse association between hypovitaminosis D and mea-
sures of insulin resistance and glycaemia in obese chil-
β Cells Glucose
Glucose
Glucose
Glucose
GLUT4
Signal transduction
???????
1,25(OH)D
Ca flux
??????????
Stimulation
Block/
inactivation
Ca????
Oxidative
metabolism
Depolarization Nucleus
????
??? ??? Insulin gene ???????
??????????????????
?????????????
???????????????????
?????
???????????????????????
? ???????????? ?????????
???????
???????????????????
Antiapoptotic
?????????????
Ca flux
1,25(OH)D
1,25(OH)D
25(OH)D
1?????????????
Insulin gene???
???????????????????????????????????????
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Nucleus
Ca ????
?????????
K+?????????????
GLUT2
25(OH)D
??????????????
1,25(OH)D Calbindin
+
+
+
+
+
+
1,25(OH)D
–
+–
+
+–
+–
–
 Fig. 2. Vitamin D and its role in glucose homoeostasis and pancre-
atic beta-cell function.  Beta cells (above): Source of  1,25(OH)D in-
cludes the circulation or the pancreatic β cells. I. 1,25(OH)D up-
regulated insulin gene transcription via VDR binding which lead 
to more insulin synthesis. II. Vitamin D improves insulin secretion 
and glucose tolerance also through indirect regulation of intracel-
lular calcium through increasing the ATP/ADP ratio resulting in 
closure of the plasma membrane ATP-gated channels and depo-
larization of the cell leading to exocytosis of insulin-containing 
secretory granules. III. Modulation of cytokine secretion and 
apoptotic pathways occurs through interaction with VDRE in cy-
tokine genes, inactivation of NF-κB and suppression of Fas recep-
tor. IV. Upregulation of calbindin may also protect against cyto-
kine-induced apoptosis by increasing intracellular free calcium. 
 Target tissues (below): I. Vitamin D stimulates the expression of 
insulin receptors and signalling transduction, resulting transloca-
tion of GLUT4 to the membrane and glucose transport in periph-
eral tissues. II. Vitamin D causes activation of peroxisome prolif-
erator-activated receptor (PPAR-δ), a transcription factor impli-
cated in the regulation of fatty acid metabolism. 
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dren  [39–41] .  Table  1 summarizes some of the recent 
studies that have investigated the association of 25(OH)
D with glucose homeostasis in children.
 In summary, observational studies investigating an as-
sociation between vitamin D status, as indicated by 
25(OH) D levels and glycaemia, diabetic risk and β-cell 
function have been performed in multiple cohorts. Despite 
the overall view in favour of a negative impact of hypovi-
taminosis D on glucose homeostasis and β-cell function, 
the available literature demonstrates inconsistent results. 
There are several possible explanations for this variation 
including differences in study design, subject characteris-
tics, study population, confounders and techniques used 
to assess glucose homeostasis and β-cell function.
 Link between Vitamin D and Glucose Homeostasis – 
Evidence from Interventional Studies 
 A possible association between vitamin D and insulin 
secretion was raised in interventional studies over three 
decades ago  [29, 42, 43] . On the other hand, other studies 
did not find any effect of vitamin D supplementation  [44–
46] . Grimnes et al.  [47] could not find any effect of 
6 months of 20,000 IU vitamin D 3 administrated orally 
twice a week to a healthy Caucasian cohort who had vita-
min D levels lower than 40.3 ± 12.8 nmol/l on both insu-
lin sensitivity and secretion. This was consistent with an-
other study which showed that the injection of two doses 
of 100,000 IU vitamin D 3 did not lower fasting glucose or 
insulin sensitivity in a Caucasian cohort  [48] . However, 
these results could not be applied to other ethnic popula-
tions as shown by the study which involved South Asian 
participants and demonstrated a significant effect of the 
administration of 4,000 IU vitamin D 3 for 6 months to 
decrease fasting glucose and increase insulin sensitivity in 
vitamin D-deficient and insulin-resistant South Asian 
women  [49] . Mitri et al.  [50] designed the short-term Cal-
cium and Vitamin D for Diabetes Mellitus (CaDDM) 2 
by 2 factorial, double-masked, placebo-controlled trial, 
which looked at the effect of vitamin D and calcium sup-
plementation alone or in combination on pancreatic 
β-cell function, insulin sensitivity and glucose tolerance 
in 92 mainly Caucasian, obese and glucose-tolerant 
adults. Study participants were divided into four groups; 
one of them taking 2,000 IU vitamin D 3 for 16 weeks. The 
deposition index which was used as an indication for pan-
creatic β-cell function was measured. The results from 
this study showed a significant increase in deposition in-
dex in the vitamin D supplement group and improve-
ment in pancreatic β-cell function by 15–30% with a ten-
dency to decrease the rise in the measure of glycaemia. A 
recent double-blind, placebo-controlled trial of obese vi-
tamin D-deficient adolescents aged 9–19 years failed to 
find any significant effect of 6 months’ supplementation 
of 4,000 IU vitamin D on BMI, inflammatory markers, 
fasting glucose and insulin  [51] . 
 In conclusion, results from interventional studies show 
some degree of inconsistency with heterogeneity of tech-
niques, study designs, subject characteristics and the ther-
apeutic regimen. Most of the available studies used indi-
rect methods to measure the effect of vitamin D on insulin 
sensitivity. Basal vitamin D levels were not available for 
most of the studies and there was no universal threshold to 
define vitamin D deficiency, insufficiency or sufficiency.
 Link between Vitamin D and Cardiovascular 
Function – Putative Mechanisms 
 Seasonal variation of cardiovascular disease was ob-
served many years ago, with higher mortality from isch-
aemic heart disease occurring in winter  [52] . A linear re-
lationship between mortality from ischaemic heart dis-
ease and higher latitude has been reported as well, with 
decreasing mortality with residence within increasing 
proximity to the equator  [53] . Results of several clinical 
and epidemiological studies have linked low vitamin D 
status to cardiovascular risk factors such as hypertension, 
diabetes, obesity and elevated blood cholesterol level  [54, 
55] .
 Vitamin D may affect cardiovascular health through 
many mechanisms. These include downregulation of 
PTH  [56] , suppression of the renin-angiotensin-aldoste-
rone system  [57] , regulation of vascular smooth muscle 
and cardiomyocyte proliferation and hypertrophy  [58, 
59] , enhancement of endothelial cell-derived vascular va-
sodilatation  [60] , regulation of coagulation  [61] , modula-
tion of inflammatory markers  [62] and metalloprotein-
ase-9 (MMP-9)  [63] , as well as improved insulin sensitiv-
ity and secretion  [64] ( fig. 3 ).
 Chronic vitamin D deficiency leads to overproduction 
of PTH, mainly due to decreased intestinal calcium ab-
sorption and increased calcium mobilization from bone. 
Overproduction of PTH can have several cardiovascular 
consequences including left ventricular hypertrophy 
(LVH), valvular calcification, myocardial calcification, 
cardiac arrhythmia and arterial hypertension  [65, 66] . 
The renin-angiotensin system (RAS) is known to play a 
vital role in controlling blood pressure, intravascular vol-
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ume and electrolyte balance. Low vitamin D levels up-
regulate the renin-angiotensin-aldosterone system, in-
crease inflammation and cause endothelial dysfunction. 
Genetic disruption of the VDR in mice results in over-
stimulation of the RAS, leading to high blood pressure 
and cardiac hypertrophy  [67] . Similarly, in humans, re-
cent studies have reported an inverse association between 
1,25(OH) 2 D 3 level, renin activity and blood pressure in 
both normal and hypertensive human subjects  [68, 69] .
 Vitamin D has been recognized as a powerful modula-
tor which can inhibit various inflammatory mediated 
processes such as atherosclerosis, myocardial infarction 
and blood clot formation. Vitamin D deficiency is report-
ed to induce atherosclerosis  [70] and enhance tissue plas-
minogen activator secretion in experimental animals 
 [71] . It has been shown to reduce MMP-9 secretion  [63] .
 Vitamin D through its VDR in heart muscle has been 
suggested to exert a direct role on the heart muscle and to 
regulate the cardiomyocyte cell cycle  [72] . Vitamin D has 
been shown to suppress cardiac cell proliferation and to 
maintain structure and function of cardiac cells directly 
through anti-inflammatory, antifibrotic and antiapoptot-
ic mechanisms  [73, 74] .
 Link between Vitamin D and Cardiovascular – 
Evidence from Observational Studies 
 The NHANES in the United States, which involved 
>16,600 subjects, showed a strong and independent as-
sociation between low vitamin D and angina, myocardial 
infarction and stroke  [75] . Marniemi et al.  [76] also found 
that both low vitamin D intake and low serum levels of 
1,25(OH) 2 D predicted acute myocardial infarction and 
stroke after a 10-year follow-up in an elderly population-
based survey. Using data from the (NHANES) 2001–2004 
study population which included 2,609 hypertensive 
adults, a linear inverse association between 25(OH)D 
concentration and cardiovascular mortality (p = 0.010) 
has been suggested, a hazard ratio of 3.2 (95% CI 1.14–
8.99) in the first quartiles (<17 ng/ml), compared with the 
highest 25(OH)D quartile ( ≥ 29 ng/ml)  [77] . The associa-
tion between low levels of vitamin D and hypertension 
has been studied and reported extensively. A cross-sec-
tional study which involved 2,722 adults recruited from 
California has reported an increased prevalence of hyper-
tension with serum levels of 25(OH)D <100 nmol/l, with 
an even higher prevalence (52%) when serum 25(OH)D 
falls <38 nmol/l  [78] .
 Results from prospective studies showed mixed re-
sults. One study found a twofold increase in the inci-
dence of myocardial infarction in vitamin D-deficient 
healthy men after a 10-year follow-up period, even after 
controlling for factors known to be associated with coro-
nary artery disease  [79] . However, another study did not 
find any significant difference in the prevalence of car-
diovascular events between vitamin D deficiency and 
sufficiency after a 4.4-year follow-up of 813 elderly men 
who had osteoporotic fractures  [80] . There is less evi-
dence from paediatric studies of the association between 
vitamin D deficiency and cardiovascular risk factors. 
One recent systematic review which looked at the asso-
Heart muscle and vasculature     Inflammation
?????????????????????????????? ? ???????????????
????????????????????????????????? ?????
????????????????????????? ? ?????
????????????????????????? ? ??????
???????????????????????????? ? ???????
? ? ? ?????????????? ????
? ? ? ????????????????????????
Cardiovascular risk factors
????????????????????????????????????
?????????????????????????????????
? ?????
? ?????
? ????????????????????
? ???????????????????
? ??????????????????
Direct effect Indirect effect
Effect on the cardiovascular system
 Fig. 3. Potential role of vitamin D on cardiovascular system. VSM = Vascular smooth muscle; CRP = C-reactive protein; VEGF = vas-
cular endothelial growth factor; HDL = high-density lipoprotein; LDL = low-density lipoprotein; TG = triglycerides. 
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ciation between 25(OH)D and cardiometabolic risk fac-
tors did not find sufficient evidence to support this as-
sociation  [81] . Most of the reviewed cross-sectional stud-
ies found an inverse relationship between systolic blood 
pressure and vitamin D  [82, 83] . Severe nutritional vita-
min D deficiency has been reported as one of the aetio-
logical factors in the development of dilated cardiomy-
opathy and significant improvement with subsequent 
vitamin D and calcium supplementation  [84, 85] .  Ta-
ble 2 summarizes some of the recent studies that have 
been conducted in children.
 Collectively, current evidence from observational stud-
ies supports the role of hypovitaminosis D in the develop-
ment and/or progression of cardiovascular disease in the 
adult population. There is insufficient evidence available 
to conclude whether or not vitamin D status in childhood 
significantly alters cardiovascular risk in adulthood.
 Link between Vitamin D and Cardiovascular – 
Evidence from Interventional Studies 
 There remains some uncertainty regarding the benefit 
of vitamin D supplementation. A single oral dose of 
100,000 IU vitamin D 3 has been shown to increase the 
serum level of 25(OH)D in vitamin D-deficient patients 
with peripheral artery diseases, without any significant 
effect on endothelial function, arterial stiffness, coagula-
tion and inflammation markers  [86] . Another study in-
volving 78 Scottish adults showed a significant effect of 
single high dose of 100,000 IU vitamin D 2 in improving 
endothelial function in patients with T2DM and low se-
rum 25-hydroxyvitamin D levels during winter  [87] . The 
Women’ Health Initiative trial failed to find any differ-
ence on cardiovascular disease outcome over a 7-year fol-
low-up period of 36,282 post-menopausal women treated 
with both 400 IU of vitamin D and 1 g calcium daily com-
pared to placebo. However, Hsia et al.  [88] and others  [89] 
found an overall trend towards a favourable effect of tak-
ing vitamin D to reduce total cardiovascular mortality 
and cancer. A meta-analysis conducted to summarize the 
available randomized trials assessing the relationship be-
tween vitamin D and cardiovascular outcomes was un-
able to find any significant effect of vitamin D on total 
mortality from cardiovascular disease (relative risk (RR) 
0.96; 95% CI 0.93–1.00; p = 0.08), myocardial infarction 
(RR 1.02; 95% CI 0.93–1.13; p = 0.64) or stroke (RR 1.05; 
95% CI 0.88–1.25; p = 0.59). Additionally, there were no 
significant changes in the other cardiometabolic risk fac-
tors such as blood pressure, lipids and blood glucose  [90] .
 Studies examining the effect of vitamin D supple-
mentation on cardiovascular events in children are 
scarce. The first randomized controlled trial involved a 
16-week administration of either 2,000 or 400 IU vita-
min D 3 in 44 healthy African-American youths aged 
14–18 years and found that the administration of vita-
min D can counteract the progression of aortic stiffness 
and there was also a negative association between adi-
posity and vitamin D level in the treatment group  [91] . 
One study of 14 post- menarcheal obese females, who 
had been treated for vitamin D deficiency, did not find 
an association between vitamin D level and blood pres-
sure but reported a beneficial effect of vitamin D on 
 glucose homeostasis. This study also indicated one pos-
sible adverse effect of vitamin D on specific ethnic 
groups as shown by a positive association between vita-
min D and lipid profile and alanine transaminase in 
 African-Americans  [92] .
 In summary, current evidence from interventional 
studies does not clearly support the use of vitamin D sup-
plementation in protecting against cardiovascular disease 
 [93, 94] . Therefore, large clinical trials with robust follow-
up are still needed. There also remains a need for assess-
ment of the effect of childhood vitamin D status on car-
diovascular disease in adulthood  [85] .
 Immune Function and Its Links to Vitamin D 
Deficiency – Putative Mechanisms 
 An immunoregulatory role for vitamin D was suggest-
ed several decades ago when sunshine was shown to in-
crease resistance to infections in experimental animals 
 [95] . The effect of seasons and/or latitude on vitamin D 
status has been discussed extensively  [96] and vitamin D 
and/or UV radiation has long been advocated as a cure 
for various illnesses and infections  [97] . The evidence for 
vitamin D as a modulator of immune responses is re-
viewed below.
 Physical Barrier and Innate Immunity 
 Innate immunity provides the first defence against ex-
ternal challenges. The first component of the innate im-
mune system consists of a combination of physical and 
chemical barriers. Expression of VDR and 1α-hydroxylase 
by epithelial cells in the respiratory passages, skin, gut and 
urogenital system suggests that vitamin D may be in-
volved in preservation of barrier integrity and maintain-
ing intracellular functions  [98, 99] . Its role in maintaining 
barrier functions is also supported by the observation that 
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vitamin D upregulates genes which encode junctional 
proteins between epithelial cells, such as tight junctions 
(e.g. occludin), gap junctions (e.g. connexion 43) and ad-
herens junctions (e.g. E-cadherin)  [100–102] . However, 
more research is needed to fully understand the role of 
vitamin D in this area.
 The second level of innate immunity is production of 
antimicrobial peptides (AMPs) such as α-defensins, 
β-defensins and cathelicidin. Vitamin D stimulates hu-
man AMP expression in different epithelial tissues such 
as bronchial  [103] , urogenital  [104] , and skin  [105] and 
also in myeloid cells  [106] . Aside from their direct micro-
bicidal role, AMPs modulate many other immune pro-
cesses, including mast cell degranulation, stimulation of 
cytokine and chemokine production, cell differentiation, 
vascular permeability, wound healing and the process of 
antigen presentation  [107–110] .
 Finally, vitamin D has been suggested to play a vital role 
at the third level of defence which is the specific immune 
response, mainly through its effect on the recruitment of 
phagocytic cells, promotion of healing and initiation of 
inflammatory responses  [111, 112] as discussed below.
 Antigen Presentation and Adaptive Immunity 
 Vitamin D has been suggested to differentially affect 
dendritic cell (DC) subsets to enable more tolerogenic 
responses, and thereby promote the development of reg-
ulatory T cells (Tregs)  [113, 114] . While leaving plasma-
cytoid DCs unaffected, 1,25(OH) 2 D 3 can block myeloid 
DC maturation, causing reduced expression of MHC 
class II, and co-stimulatory molecules  [115] . Both mac-
rophages and DCs express increasing levels of 
1α-hydroxylase during maturation into antigen-present-
ing cells (APCs). In DCs, the outcome of this is that both 
vitamin D and its metabolite (25-OHD 3 ) are able to sup-
press the differentiation and function of these cells. 
When the APCs mature, their ability to produce active 
vitamin D is increased but they expresses less VDRs. The 
vitamin D from mature APCs has been suggested to act 
in a paracrine fashion on neighbouring immature APCs 
to trigger more antigen presentation, whilst the ability of 
mature APCs to decrease VDR expression prevents over-
stimulation  [116] .
 T cells also express the VDR and appears to be a direct 
target of vitamin D  [117] . T cells were traditionally divided 
into T-helper (Th) cells (CD4+) – responsible for regulat-
ing T- and B-cell responses and cytotoxic T cells (CD8+) – 
capable of killing target cells such as virally infected cells or 
tumour cells. More recently, additional subsets have been 
identified including Tregs and several functionally distinct 
Th cell subsets including Th1, Th2 and Th17 cells. Tregs are 
crucial for the maintenance of immunological self-toler-
ance, whilst the Th cell subsets secrete different patterns of 
cytokines resulting in distinct immune responses. An im-
balance in the Th1/Th2 immune response has been impli-
cated in the pathogenesis autoimmune disorders  [118] . Vi-
tamin D suppresses effector T-cell function, influences Th 
subsets, and stimulates Tregs  [119, 120] . Th cells have been 
found to be a main target of vitamin D  [121] which inhibits 
production of Th1-related cytokines such as TNF-α and 
IFN-γ, whilst promoting Th2 cytokines such as interleukin 
(IL)-4 and IL-5  [122, 123] . However, other studies could 
not confirm these findings  [124] . Th17 cells are a recently 
discovered subset of Th cells, which are thought to be im-
portant in the pathogenesis of autoimmune diseases such 
as multiple sclerosis and rheumatoid arthritis. Vitamin D 
also downregulates Th17-secreted cytokines such as IL-17 
and IL-21  [124, 125] . Therefore, vitamin D deficiency may 
promote autoimmune diseases through both direct and in-
direct roles in regulating Th1/Th17 and Treg function in 
addition to skewing cytokine production towards a Th2 
phenotype  [118] .
 Finally, a number of reports indicate that vitamin D 
can inhibit the generation of memory B cells from naive 
B cells, inhibit B-cell proliferation, induce apoptosis and 
suppress immunoglobulin secretion and maintain the de-
velopment and function of natural killer cells  [126, 127] . 
 Figure 4 shows the potential role of vitamin D in the dif-
ferent components of the immune system.
 Link between Vitamin D and Immune Function – 
Evidence from Observational Studies 
 Clinical associations between the prevalence of im-
mune-related illness and vitamin D deficiency have been 
reported widely in the literature. Results from most ob-
servational studies report an inverse relationship between 
vitamin D status and the risk of acute respiratory tract 
infection, tuberculosis and pneumonia in both paediatric 
and adult populations  [128–131] . In addition, there is a 
strong association between vitamin D and the prevalence 
of oral  [132, 133] , gastrointestinal  [134] , urinary tract 
 [104] and ocular infections  [135] . The impact of vitamin 
D on several dermatological conditions such as wound 
healing, psoriasis, atopic dermatitis and acne has been 
also has been reported  [136–140] . Finally, several autoim-
mune diseases such as inflammatory bowel diseases, mul-
tiple sclerosis, systemic lupus erythematosus, type 1 dia-
betes mellitus and rheumatoid arthritis have been re-
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viewed. Again, significant associations between a low 
vitamin D and the prevalence autoimmune disorders 
were reported  [141–144] .
 Link between Vitamin D and Immune Function – 
Evidence from Interventional Studies 
 Despite these strong observational and theoretical 
links between vitamin D and immune system disorders, 
interventional studies looking at the therapeutic effect of 
vitamin D supplementation show conflicting results. In a 
randomized double-blind study, 4,000 IU of vitamin D 3 
daily for 1 year in patients with an immune disorder and 
frequent attacks of acute respiratory tract infection 
showed a 23% decrease in the number of attacks and 60% 
reduction of antibiotic use  [145] . However, in another 
trial using healthy adults, administration of vitamin D did 
not affect the severity or prevalence of acute respiratory 
tract infection  [146, 147] . In one study, high-dose vitamin 
D supplementation was reported to accelerate clinical 
and radiological improvement in pulmonary tuberculosis 
patients  [148] . However, others reported no effect  [149] . 
A recent systematic review of randomized, placebo dou-
ble-blind trials assessing the beneficial of vitamin D ad-
ministration in patients with multiple sclerosis was un-
able to reach a verdict with no significant effect seen in 4 
out of 5 available trials  [150] . Although there are limited 
studies looking at the effect of vitamin D intervention in 
children, most publications show a beneficial effect of vi-
tamin D supplementation on reducing acute respiratory 
tract infections  [151, 152] . A randomized controlled trial 
looking at the effect of 100,000 IU of vitamin D supple-
mentation in South Asian children with pneumonia 
VDR, CYP27B1
Antigen presentation
Proliferation
Cathelicidin production
Cytokine production
(? inflammatory)
Superoxide production
(monocytes)
? Maintaining barrier integrity, intracellular functions and cell communication
? ? Production and expression of AMPs such as cathelicidin and ??????????????????????????????????
 macrophages and neutrophils
?????????????????? ????????????????????????????????
??????????????????????????????????? ????????
?????????????????????????????????????????????
???? ????????????
?????????????????????????????????????????
VDR, CYP27B1
Antigen presentation
? Maturation
???????????????????????
MHC class II, CD83 and co-
??? ???????? ???????????????
??????????????
???????????????????????????
?????????????????????
??????????
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?????????????????????
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?????????????????
???????????????????
cytokine production
(???????????????? anti-
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 Fig. 4. Modulation of different components of the immune system. 
Potential action of systemic or locally synthesized vitamin D on 
different components of immune system and immune-cell types. 
NK cells = Natural killer cells; CYP27B1 (25-hydroxyvitamin D 3 -
1α-hydroxylase)  = cytochrome P450 enzyme that catalyzes the 
conversion of 25-hydroxyvitamin D 3 (25(OH)D) to 1α,25-
dihydroxyvitamin D 3 (1,25(OH) 2 D); MHC class ІІ = major histo-
compatibility complex  class II molecules; Treg = forkhead box pro-
tein 3 (FOXP3) + Treg cells; IgG = immunoglobulin G; IgM = im-
munoglobulin M. 
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showed a reduced number of repeat attacks in the vitamin 
D group (58%; RR 0.78; 95% CI 0.64–0.94; p = 0.01)  [153] . 
However, supplementation with the same dose once ev-
ery 3 months for a period of 18 months did not reduce the 
prevalence of pneumonia in high-risk South Asian in-
fants  [154] .  Table 3 summarizes some of recent clinical 
studies which have been conducted in children.
 In summary, scientific studies support an important 
role for vitamin D in many aspects of the immune re-
sponse. Clinical evidence from observational studies shows 
a strong correlation between vitamin D deficiency and de-
velopment of various immune and infectious diseases.
 Conclusion 
 The numbers of reports that highlight possible thera-
peutic actions of vitamin D have increased over the last 
decade. Initial observational studies have indicated that 
vitamin D deficiency may be associated with impair-
ment in glucose homeostasis, increase cardiovascular 
risk and immune dysfunction. However, interventional 
studies have been inconsistent and there is a need for 
more detailed and larger-scale studies to clarify the 
therapeutic benefit of vitamin D in these important 
clinical areas. 
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